Adjuvant immunotherapy for renal cell carcinoma
-
Published:2022-09
Issue:9
Volume:23
Page:1110-1111
-
ISSN:1470-2045
-
Container-title:The Lancet Oncology
-
language:en
-
Short-container-title:The Lancet Oncology
Author:
Sendur Mehmet Ali Nahit
Reference10 articles.
1. Prognostic factors in renal cell carcinoma;Volpe;World J Urol,2010
2. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial;Haas;Lancet,2016
3. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial;Gross-Goupil;Ann Oncol,2018
4. Adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma: final overall survival analysis of the phase 3 PROTECT trial;Motzer;Eur Urol,2021
5. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy;Ravaud;N Engl J Med,2016
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献